REPLIGEN CORP Annual Operating Income (Loss) in USD from 2009 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Repligen Corp quarterly/annual Operating Income (Loss) history and growth rate from 2009 to 2023.
  • Repligen Corp Operating Income (Loss) for the quarter ending September 30, 2024 was -$7.83M, a 267% decline year-over-year.
  • Repligen Corp Operating Income (Loss) for the twelve months ending September 30, 2024 was $11.3M, a 87% decline year-over-year.
  • Repligen Corp annual Operating Income (Loss) for 2023 was $47.7M, a 78.8% decline from 2022.
  • Repligen Corp annual Operating Income (Loss) for 2022 was $225M, a 34.3% increase from 2021.
  • Repligen Corp annual Operating Income (Loss) for 2021 was $167M, a 140% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $47.7M -$177M -78.8% Jan 1, 2023 Dec 31, 2023 10-K/A 2024-11-18
2022 $225M +$57.4M +34.3% Jan 1, 2022 Dec 31, 2022 10-K/A 2024-11-18
2021 $167M +$97.4M +140% Jan 1, 2021 Dec 31, 2021 10-K/A 2024-11-18
2020 $69.8M +$33.7M +93.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-22
2019 $36.1M +$10.1M +38.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-17
2018 $26M +$12M +85.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
2017 $14M -$1.97M -12.3% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $16M +$2.21M +16.1% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-01
2015 $13.8M +$3.07M +28.7% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-22
2014 $10.7M -$12.2M -53.3% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-23
2013 $22.9M +$11.8M +106% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-25
2012 $11.1M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-17
2010 -$374K +$5.39M +93.5% Apr 1, 2010 Mar 31, 2011 10-K 2013-03-15
2009 -$5.77M Apr 1, 2009 Mar 31, 2010 10-K 2012-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.